我武生物：豚草花粉点刺液药物临床试验补充申请获批准

Core Viewpoint - The company has received approval for a supplementary application for clinical trials of "Artemisia pollen prick solution" from the National Medical Products Administration, allowing for an increase in total allergen activity to 3500 DU/ml with a packaging specification of 2 ml per bottle [1] Group 1 - The company has downloaded the "Approval Notification for Supplementary Application of Drug Clinical Trials" from the National Medical Products Administration [1] - The approved supplementary application pertains to the "Artemisia pollen prick solution" [1] - The new specification allows for a total allergen activity of 3500 DU/ml [1]